News & Updates

Revered by diet enthusiasts as a godsend in the weight loss arena, a low-carbohydrate, high-fat (LCHF*) diet appears to take the opposite pole from a cardiovascular (CV) standpoint, as researchers from Canada found high levels of bad cholesterol and apolipoprotein B (apoB) in individuals who adhered to this dietary pattern.

Combination therapy with metformin and thiazolidinedione appears to be the best performing glucose-lowering medication for preventing atrial fibrillation (AF) in patients with type 2 diabetes (T2D), as shown in a study.

Time-restricted eating does not appear to be more effective than daily calorie restriction in terms of improving intrahepatic triglyceride content, body fat, and metabolic risk factors for adults with obesity and nonalcoholic fatty liver disease (NAFLD), according to a study.

The polyphenol-rich spice cinnamon has the potential to modulate imbalances in lipid profile for certain individuals with metabolic disorders, particularly those with polycystic ovarian syndrome, according to the results of an umbrella meta-analysis.

A coordinated, multifaceted intervention of assessment, education, and feedback has resulted in an increase in the prescription of recommended, evidence-based therapies in adult patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (CVD), reveals a study presented at ACC 2023.

Low use of recommended monitoring tests, including repeat prostate biopsy, persists among patients with localized prostate cancer undergoing observation, a recent study has found.

A full, therapeutic dosing of anticoagulation flops for reducing the incidence of overall combined outcomes in noncritically ill patients hospitalized with COVID-19 as compared with prophylactic dosing, although there is a signal of benefit for mortality and disease progression with the therapeutic dosing, as shown in the FREEDOM COVID trial presented at ACC.23/WCC.

Maintenance treatment with 5-aminosalicylates (5-ASA) in patients with newly diagnosed Crohn's disease (CD) does not appear to lead to better outcomes as compared with a watchful waiting approach, according to a study.

Among patients with metastatic renal cell carcinoma (RCC) who have received first-line therapies, complete response rates are lower in the real-world population than in the clinical trial population, reports a recent study. Complete response predicts a favourable overall survival.